Award
NIH Reporter #5R37CA283552-02
Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC)
Recipient
Israel Canadas
Award Amount
$649,679.00
Ceiling
$649,679.00
Awarded
August 06, 2025
Identifier
5R37CA283552-02
This multi-year research contract is awarded to a scientific organization in Philadelphia, focusing on developing a small molecule inhibitor targeting the RNA/DNA helicase DHX9. The project aims to induce viral mimicry in Small Cell Lung Cancer (SCLC) to enhance the effectiveness of immunotherapy treatments. The award signifies a substantial investment in innovative cancer research, with the work involving the design and evaluation of novel therapeutic compounds. The contract is a sole-source award, emphasizing its targeted and specialized nature. The project timeline is ongoing, with the initial award establishing a foundation for future translational studies in cancer immunotherapy.
Description
Research project focused on targeting the RNA/DNA helicase DHX9 to induce viral mimicry and enhance immunotherapy responsiveness in Small Cell Lung Cancer. The project involves developing a small molecule inhibitor of DHX9 to evaluate its translational relevance in cancer treatment and immunotherapy.